Ubs Group Ag Exscientia PLC Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Exscientia PLC stock. As of the latest transaction made, Ubs Group Ag holds 92,395 shares of EXAI stock, worth $447,191. This represents 0.0% of its overall portfolio holdings.

Number of Shares

92,395

Previous 11,769 685.07%

Holding current value

$447,191

Previous $60,000 650.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.26 - $6.0 $343,466 - $483,756	80,626 Added 685.07%	92,395 $450,000
Q2 2024 Aug 13, 2024	BUY	$3.99 - $6.04 $7,876 - $11,922	1,974 Added 20.15%	11,769 $60,000
Q1 2024 May 13, 2024	SELL	$5.3 - $7.51 $17,346 - $24,580	-3,273 Reduced 25.05%	9,795 $56,000
Q4 2023 Feb 09, 2024	BUY	$4.35 - $6.88 $1,818 - $2,875	418 Added 3.3%	13,068 $83,000
Q3 2023 Nov 09, 2023	BUY	$4.52 - $8.9 $30,745 - $60,537	6,802 Added 116.31%	12,650 $57,000
Q2 2023 Aug 11, 2023	SELL	$4.79 - $8.3 $10,241 - $17,745	-2,138 Reduced 26.77%	5,848 $34,000
Q1 2023 May 12, 2023	BUY	$5.3 - $10.93 $4,653 - $9,596	878 Added 12.35%	7,986 $42,000
Q4 2022 Feb 08, 2023	BUY	$4.1 - $8.94 $27,912 - $60,863	6,808 Added 2269.33%	7,108 $37,000
Q3 2022 Nov 10, 2022	SELL	$7.27 - $12.92 $2,399 - $4,263	-330 Reduced 52.38%	300 $2,000
Q2 2022 Aug 10, 2022	BUY	$6.92 - $15.97 $1,591 - $3,673	230 Added 57.5%	630 $7,000
Q1 2022 May 16, 2022	SELL	$11.52 - $22.05 $139,610 - $267,223	-12,119 Reduced 96.8%	400 $6,000
Q4 2021 Feb 14, 2022	BUY	$17.63 - $27.1 $220,709 - $339,264	12,519 New	12,519 $248,000

Others Institutions Holding EXAI

# of Institutions

100

Shares Held

33.5M

Call Options Held

500

Put Options Held

189K

View Full List

About Exscientia plc

Ticker EXAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,461,000
Market Cap $593M
Description
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on s...

More about EXAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account